Abstract
Objective: Bone is one of the most common sites of metastases in human small cell lung cancer (SCLC) which is often associated with skeletal-related events and poor prognosis. To explore the significance of Paeonol (Pae) in SCLC, we hypothesize that Pae can inhibit cell proliferation, migration and invasion, finally inhibit bone metastases of SCLC.
Methods: The effects of Pae on proliferation of SCLC were detected by MTT assay in vitro. The effects of Pae on migration and invasion of SCLC were detected by Transwell assay in vitro. Furthermore, bone chip adhesion assay was used to explore the effects of Pae on the strength of bone adhesion and metastatic ability in SCLC cell line.
Results: MTT results showed that Pae suppressed SCLC cell proliferation in a dose-dependent manner. Transwell assay results showed Pae suppressed SCLC cell migration and invasion in a dose-dependent manner. Furthermore, the cells treated by Pae showed decreased ability of bone adhesion and bone metastases in vitro compared with control.
Conclusions: The study indicated Pae could suppress bone metastases of SCLC cells and Pae might be a promising medicine for therapy of SCLC bone metastases.
Keywords: Bone metastases, pae, small cell lung cancer.
Graphical Abstract
Current Signal Transduction Therapy
Title:Paeonol Inhibits Migration, Invasion and Bone Adhesion of Small Cell Lung Cancer Cells
Volume: 10 Issue: 2
Author(s): Yong Tian, Cong Chen, Yu Zhang, Zhen Zhang and Haiyan Xie
Affiliation:
Keywords: Bone metastases, pae, small cell lung cancer.
Abstract: Objective: Bone is one of the most common sites of metastases in human small cell lung cancer (SCLC) which is often associated with skeletal-related events and poor prognosis. To explore the significance of Paeonol (Pae) in SCLC, we hypothesize that Pae can inhibit cell proliferation, migration and invasion, finally inhibit bone metastases of SCLC.
Methods: The effects of Pae on proliferation of SCLC were detected by MTT assay in vitro. The effects of Pae on migration and invasion of SCLC were detected by Transwell assay in vitro. Furthermore, bone chip adhesion assay was used to explore the effects of Pae on the strength of bone adhesion and metastatic ability in SCLC cell line.
Results: MTT results showed that Pae suppressed SCLC cell proliferation in a dose-dependent manner. Transwell assay results showed Pae suppressed SCLC cell migration and invasion in a dose-dependent manner. Furthermore, the cells treated by Pae showed decreased ability of bone adhesion and bone metastases in vitro compared with control.
Conclusions: The study indicated Pae could suppress bone metastases of SCLC cells and Pae might be a promising medicine for therapy of SCLC bone metastases.
Export Options
About this article
Cite this article as:
Tian Yong, Chen Cong, Zhang Yu, Zhang Zhen and Xie Haiyan, Paeonol Inhibits Migration, Invasion and Bone Adhesion of Small Cell Lung Cancer Cells, Current Signal Transduction Therapy 2015; 10 (2) . https://dx.doi.org/10.2174/1574362410666150625191130
DOI https://dx.doi.org/10.2174/1574362410666150625191130 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Synthesis and In Vitro Antitumor Activity of Novel Fluorine Containing Pyrazoles and Pyrazolines
Letters in Drug Design & Discovery Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging New Developments in the Management of Pleural Effusions
Current Respiratory Medicine Reviews QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Ferulenol, a Sesquiterpene Coumarin, Induce Apoptosis via Mitochondrial Dysregulation in Lung Cancer Induced by Benzo[a]pyrene: Involvement of Bcl2 Protein
Anti-Cancer Agents in Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Experimental Therapy for Lung Cancer: Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Interleukin-24 Delivery
Current Cancer Drug Targets Dynamical Behaviors of the Transcriptional Network Including REST and miR-21 in Embryonic Stem Cells
Current Bioinformatics Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry HPLC-NMR Chemical Profiling of the Australian Carnivorous Plant, Drosera erythrohiza subspecies magna
The Natural Products Journal Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl) amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
Current Nanoscience Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design YB-1 Protein and Multidrug Resistance of Tumor Cells
Current Signal Transduction Therapy Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets